Search results for: HTA

Dr Tina Wang

11 November 2024

…project managing the CIRS HTA Programme and coordinating a HTA steering committee, executing and implementation of metrics studies evaluating the HTA processes within companies and agencies on annual basis, conducting…

What is the Role of HTA for Biosimilars?

1 April 2014

This Briefing summarises the results of a roundtable convened by OHE to discuss using HTA to assess biosimilars – including which methods are most appropriate in specific situations. Participating were…

OHE at HTAi 2018

29 May 2018

…International (HTAi) 2018 conference in Vancouver, 1-5 June. Later this week, Adrian Towse, Koonal Shah, Grace Hampson, and Chris Sampson will be travelling to Vancouver, Canada, to participate in HTAi…

OHE Lunchtime Seminar: ‘Age, Utilities, and Self-Reported Health: Issues for HTA’

17 May 2016, 11:00pm

…health: issues for HTA’. Occasionally, in health technology assessments (HTA), the situation arises that the central estimate of patients’ HRQoL available from clinical trials exceeds that of the general population…

The Future of NICE in a Changing HTA Landscape

27 March 2024, 2:00pm

…our moderator, Chris Sampson (Senior Principal Economist, OHE). These interviews captured the most pressing issues and advancements in HTA, exploring what the future of HTA will look like over the coming years.  The…

OHE and ABPI Webinar: New EQ-5D-5L value sets for England and the UK and Implications for HTA

11 July 2016

…for England and the UK and implications for HTA. The EQ-5D is one of the most widely used generic measures of health related quality of life (HRQL), and is the…

New OHE Research Paper: Uncertainty and Risk in HTA Decision Making

7 December 2016

…it affects the cost effectiveness aspects of HTA. A new OHE Research Paper has just been published on the topic of uncertainty and risk in health technology assessment (HTA) decision…

OHE at ISPOR’s 20th Annual European Congress: Presentations

…and challenges of applying MCDA in HTA. Adrian Towse discussed the challenges of conducting HTA of gene therapies as part of an ISPOR issue panel. He explained that gene therapy…

A global landscape analysis of access to tumour-agnostic therapies 

1 December 2025

…approach, requiring additional evidence to support TA-based indications and restricting indications when considerable treatment heterogeneity was observed. HTA Challenges: TA therapies challenge traditional HTA frameworks, which are designed for organ-specific…